- Home
- KPTI vs USEG Comparison
KPTI vs USEG Comparison
Compare KPTI & USEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- USEG
- Stock Information
- Founded
- KPTI 2008
- USEG 1966
- Country
- KPTI United States
- USEG United States
- Employees
- KPTI N/A
- USEG N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- USEG Oil & Gas Production
- Sector
- KPTI Health Care
- USEG Energy
- Exchange
- KPTI Nasdaq
- USEG Nasdaq
- Market Cap
- KPTI 81.1M
- USEG 80.1M
- IPO Year
- KPTI 2013
- USEG N/A
- Fundamental
- Price
- KPTI $0.63
- USEG $2.08
- Analyst Decision
- KPTI Strong Buy
- USEG Strong Buy
- Analyst Count
- KPTI 4
- USEG 2
- Target Price
- KPTI $5.00
- USEG $2.75
- AVG Volume (30 Days)
- KPTI 760.2K
- USEG 11.5M
- Earning Date
- KPTI 02-19-2025
- USEG 03-25-2025
- Dividend Yield
- KPTI N/A
- USEG N/A
- EPS Growth
- KPTI N/A
- USEG N/A
- EPS
- KPTI N/A
- USEG N/A
- Revenue
- KPTI $148,442,000.00
- USEG $22,257,000.00
- Revenue This Year
- KPTI $4.47
- USEG N/A
- Revenue Next Year
- KPTI $7.35
- USEG $12.17
- P/E Ratio
- KPTI N/A
- USEG N/A
- Revenue Growth
- KPTI 1.77
- USEG N/A
- 52 Week Low
- KPTI $0.58
- USEG $0.81
- 52 Week High
- KPTI $1.70
- USEG $6.40
- Technical
- Relative Strength Index (RSI)
- KPTI 45.85
- USEG 47.45
- Support Level
- KPTI $0.58
- USEG $2.13
- Resistance Level
- KPTI $0.67
- USEG $3.56
- Average True Range (ATR)
- KPTI 0.04
- USEG 0.24
- MACD
- KPTI -0.00
- USEG -0.06
- Stochastic Oscillator
- KPTI 42.37
- USEG 7.50
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.